Press Releases
2010
March
03/11/2010XOMA Reports 2009 and Fourth Quarter Financial Results
03/04/2010
XOMA to Announce 2009 and Fourth Quarter Financial Results and Host Conference Call on March 11
February
02/25/2010XOMA to Webcast Presentations From Two March 2010 Investment Conferences
02/09/2010
XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients
02/03/2010
XOMA Announces Presentation at BIO CEO and Investor Conference on February 9
02/02/2010
XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants
January
01/19/2010XOMA Reviews Priorities for 2010 and 2009 Accomplishments
2009
December
12/22/2009XOMA Reports Removal of "Going Concern" Qualification
12/10/2009
XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference
12/09/2009
XOMA Announces NASDAQ Matter Resolved With Letter of Reprimand
November
11/19/2009XOMA Receives NASDAQ Determination Letter
11/17/2009
XOMA Appoints Jim Neal Vice President of Business Development
11/12/2009
XOMA 052 Selected as a Top Ten Project to Watch
11/11/2009
XOMA Announces Presentation at Lazard Healthcare Conference on November 18
11/09/2009
XOMA Reports 2009 Third Quarter Financial Results
11/06/2009
XOMA Expands Development Strategy for XOMA 052 to Include Cardiovascular Diseases
11/04/2009
Phase 2 Trial of XOMA 052 to be Initiated in Type 1 Diabetes Patients
11/04/2009
XOMA Granted First European Patent Covering XOMA 052
11/03/2009
XOMA to Announce Third Quarter 2009 Financial Results and Host Conference Call on November 9
11/03/2009
XOMA Signs Antibody Discovery Collaboration With Kaketsuken
October
10/20/2009XOMA Presents First XOMA 052 Cardiovascular Disease Animal Model Results
10/14/2009
XOMA Appoints Susan Kramer, Dr. P.H. Vice President of Project and Alliance Management
10/01/2009
XOMA Announces Initiation of Its Phase 2 Clinical Program for XOMA 052 in Type 2 Diabetes and Cardiovascular Disease
September
09/30/2009XOMA Announces $13.9 Million Financing
09/30/2009
XOMA Presents Results Demonstrating Novel Mechanism of Action for XOMA 052 in Regulating IL-1 Beta Levels
09/24/2009
XOMA Completes Full Repayment of Goldman Sachs Loan
09/23/2009
XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International
09/21/2009
XOMA Receives Anticipated Deficiency Notice From NASDAQ
09/14/2009
XOMA Announces Plan to Fully Repay Goldman Sachs Loan
09/09/2009
XOMA Announces $6 Million Antibody Discovery Collaboration With Arana Therapeutics
09/04/2009
XOMA to Present At Two Upcoming Investor Conferences
August
08/10/2009XOMA to Present At Canaccord Adams Global Growth Conference On August 12, 2009
08/06/2009
XOMA Reports 2009 Second Quarter Financial Results
08/03/2009
XOMA to Announce Second Quarter 2009 Financial Results and Host Conference Call on August 6
July
07/30/2009XOMA Announces New U.S. Government Biodefense Subcontract for Development of Therapeutic Antibodies to Treat SARS
07/14/2009
XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes
07/07/2009
XOMA Announces Conference Call and Webcast On July 14 to Review Top Line Multi-dose and Other Results of Its Phase 1 Clinical Trial of XOMA 052 in Type 2 Diabetes
June
06/08/2009XOMA Presents Data At ADA Demonstrating Improvement in Diabetes and Inflammatory Measures in Animal Model With XOMA 052
06/06/2009
XOMA 052 Clinical Results Support Novel Anti-Inflammatory Approach to Type 2 Diabetes Treatment
06/05/2009
XOMA Announces $12.0 Million Financing
06/04/2009
XOMA to Present At Annual Needham Life Sciences Conference On June 10, 2009
May
05/26/2009XOMA Announces Clinical and Preclinical Presentations At American Diabetes Association 69th Scientific Sessions
05/15/2009
XOMA Announces $10 Million Financing
05/14/2009
XOMA Royalties On CIMZIA(r) Expected to Increase Due to FDA Approval for Moderate to Severe Rheumatoid Arthritis in Adults
05/12/2009
XOMA Issued New U.S. Patent Covering Its XOMA 052 Lead Product Candidate
05/07/2009
XOMA Reports 2009 First Quarter Financial Results
05/05/2009
XOMA to Present At Canaccord Adams Diabetes & Obesity Conference on May 12, 2009
05/01/2009
XOMA to Announce First Quarter 2009 Financial Results and Host Conference Call On May 7
April
04/30/2009Enrollment Completed in Phase 1 Program for XOMA 052 in Type 2 Diabetes
March
03/16/2009XOMA to Present At Cowen Health Care Conference On March 18, 2009
03/11/2009
XOMA Reports 2008 Financial Results
03/04/2009
XOMA Initiates Phase 2a Clinical Trial With XOMA 052 in Patients With Rheumatoid Arthritis
03/04/2009
XOMA to Announce Fourth Quarter 2008 Financial Results and Host Conference Call On March 11
